Showing results (31-40 of 79) with videos related to

Sort By:
Pageof 8
Plos Pathogens|May 29, 2007
Centrosomal latency of incoming foamy viruses in resting cellsJacqueline Lehmann-Che, Noémie Renault, Marie Lou Giron, et al.
Oncoimmunology|September 26, 2015
Phenotypic analysis of T cells infiltrating colon cancers: Correlations with oncogenetic statusMircea Chirica, Lionel Le Bourhis, Jacqueline Lehmann-Che, et al.
Journal of Cutaneous Pathology|November 26, 2020
Spindle cell tumor with CD34 and S100 co-expression and distinctive stromal and perivascular hyalinization showing EML4-ALK fusionDiane Abs, Samuel Landman, Amélie Osio, et al.
The American Journal of Pathology|May 13, 2014
Orthotopic animal model of pseudomyxoma peritonei: An in vivo model to test anti-angiogenic drug effectsAnthony Dohan, Ruben Lousquy, Clarisse Eveno, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 9, 2010
Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancerDavid Groheux, Sylvie Giacchetti, Jean-Luc Moretti, et al.
Plos One|July 10, 2015
IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma PatientsAymeric Amelot, Patricia De Cremoux, Véronique Quillien, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 31, 2026
A combinatorial EVs-miRNA signature mediates the anti-tumoral activity of NFAT3-regulated extracellular vesicles in aggressive cancersGuénolé Tossou, Nadia Ourari, Maëlle Ralu, et al.
Oncotarget|April 18, 2018
18FDG-PET/CT and molecular markers to predict response to neoadjuvant chemotherapy and outcome in HER2-negative advanced luminal breast cancers patientsPatricia de Cremoux, Lucie Biard, Brigitte Poirot, et al.
The American Journal of Surgical Pathology|March 19, 2021
NUT Is a Specific Immunohistochemical Marker for the Diagnosis of YAP1-NUTM1-rearranged Cutaneous Poroid NeoplasmsNicolas Macagno, Thibault Kervarrec, Pierre Sohier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2011
Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancersCharles Coutant, Roman Rouzier, Yuan Qi, et al.
Pageof 8